{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 20 of 51', 'Study ID RCB: 2020-A00652-37', '8', 'Research Question and Objectives', '8.1 Primary Objective', 'The primary endpoint will be the evaluation at week 12/16 of the sensitivity and the specificity,', 'compared to the DLQI as a standard, of the PSO-TARGET QoL component grid to assess the', 'level of satisfaction of patient achieving the therapeutic goal, identified by himself.', 'The therapeutic objective will be considered as achieved if the patient gives the responses', '\"Satisfied\" or \"Very Satisfied\" on the Likert scale. The response will then be compared to the', 'DLQI score at 12/16 weeks.', '8.2 Secondary Objectives', '- Evaluate the percentage of patients who consider their target objective as being achieved', 'after 12/16 weeks of treatment as defined by a \"satisfied or very satisfied\" response.', '-', 'Level of concordance between the satisfaction level in regard to the therapeutic', 'objective set by the PSO-TARGET QoL Component grid and the DLQI at the 2nd follow-up', 'visit (52 4 weeks.).', '-', 'Evaluate the level of agreement between the dimensions reported by the patient and by', 'the treating physician at baseline.', '-', 'Follow the degree of completeness of the main treatment goal identified at baseline after', '52 weeks.', '-', 'Follow evolution of the PASI score (at 12/16 and 52 weeks).', '-', 'Level of accordance between PASI 90/100 and the satisfaction level in regard to the', 'therapeutic objective set by the PSO-TARGET QoL Component grid.', '-', 'Follow evolution of the DLQI score (at 12/16 and 52 weeks).', '-', 'Evaluate the rate of patients who change their therapeutic objective after 12/16 weeks', 'of treatment.', '9', 'Research Method', '9.1 Study Design', '9.1.1', 'Eligibility criteria', 'The inclusion criteria are the following:', 'Age > 18 years', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 21 of 51', 'Study ID RCB: 2020-A00652-37', 'Patient for whom the dermatologist decided to initiate a treatment by Kyntheum', 'according to SmPC.', 'Patient who signed an informed consent.', 'The following non-inclusion criteria will be applied:', 'Vulnerable subjects according to the law;', 'pregnant, parturient or breast feeding women;', 'deprived of their freedom by administrative, medical or legal decision or', 'who is under trusteeship/guardianship;', 'legally protected, or unable to express their consent to participate;', 'With no affiliation to a social security system;', 'Psychologically/linguistically unable to express their consent to participate;', 'With an hypersensitivity to at least one of the excipients of Kyntheum', 'Participating at the same time in another clinical trial.', '9.1.2 PSO-TARGET Quality of Life Component grid.', 'As a first step to construct the component grid, a retrospective survey based on the', \"recollection and experience from 3 clinical dermatologists (2 French and 1 Belgian) of patient's\", 'expectations, has been conducted. The results of the survey have been used to generate a grid', 'containing 12 therapeutic goals equally distributed into the 4 major psychometric components', 'classically used in quality of life studies in patients suffering from chronic diseases (Chassany,', '2003; Forestier et al., 2019). These four dimensions (cf table 1) are the following:', '- Physical: autonomy, physical capabilities, ability to perform daily activities;', '- Subjective: linked to experienced emotion, anxiety, well-being;', '-', 'Relational/social: with family, friendship or professional environment, engaging', 'personal relationships, involvement in social or leisure activities;', '- Therapeutic: linked to treatment, for ex. treatment-/care-related discomfort.', 'The investigators participating to the study will agree to implement this table as part of their', 'standard of care along with the DLQI questionnaire.', 'Table 1: Quality of Life (QoL) component grid', 'Physical', 'Subjective', 'Relational/social', 'Therapeutic', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 22 of 51', 'Study ID RCB: 2020-A00652-37', 'Not be', 'Think less or not at all about', 'Spend quality time with family,', 'Need to think less about', 'limited/handicaped by', 'the disease', 'friends or colleagues', 'treatment and care', 'the pain', 'Do not feel any', 'functional discomfort', 'Do not feel any anxiety from', 'Not caring about what people think', 'Encounter very few, if any,', '(itching, rash) in my', 'the disease', 'about me', 'drug discomfort', 'daily activities', 'Have freedom of', 'Feel serene, have peace of', 'movement and', 'Have a fulfilling intimate life', 'To be cured quickly', 'mind', 'activities', 'This grid will be administered to the enrolled patients after signature of the informed consent.', 'The patient will be requested to identify what would be his/her main treatment objective.', 'Only one item from the list will be picked by the patient. The investigator must not influence', 'the patient into choosing a specific component to the table. The patient will have a grid with', '12 proposals in front of him/her and will not be aware of the dimensions to which the', 'proposals relate. The four dimensions typically described in chronic diseases will be considered', 'only for analysis, but not submitted to patients. The patient will be given some space and time', 'to choose the component without any help or supervision from the investigator. This is', 'requested in order to avoid social desirability, defined as the tendency of some respondents', 'to report an answer in a way they deem to be more socially acceptable than would be their', '\"true\" answer. The patient will then conceal his/her response in a provided envelope without', 'revealing the chosen component to the physician.', 'In the meantime, the treating physician will identify the therapeutic objective that is', 'supposedly the most important for his patient, based on his/her discussion with him. The', 'physician-reported component will be concealed in a separate envelope and compared with', 'the patient-chosen component during the analysis of the secondary endpoints.', 'As the primary endpoint of the study, the level of achievement of this therapeutic goal at 3', 'months (12/16 weeks) will be assessed by a 4-points Likert scale (Very Unsatisfied; Unsatisfied;', 'Satisfied; Very Satisfied), and compared to the DLQI scoring classes.', '9.1.3 Dermatology Quality of Life Index (DLQI)', 'The DLQI is designed to measure the health-related quality of life of adult patients suffering', 'from a skin disease. It can be administered in patients aged 16 years and over and takes only', \"few minutes to complete. The DLQI consists of 10 questions concerning patients' perception\", 'of the impact of skin diseases on different aspects of their health-related quality of life over', 'the last week. It is not specific to psoriasis and is the most frequently used patient reported', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}